Octanorm

BIOLOGICAL2 trials

Sponsors

Octapharma

Conditions

DermatomyositisPrimary Immune Deficiency Disorder

Phase 3

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

TerminatedNCT03686969

OctapharmaDermatomyositis

Start: 2018-08-02End: 2018-11-29Updated: 2021-04-23

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

CompletedNCT03988426

OctapharmaPrimary Immune Deficiency Disorder

Start: 2017-03-07End: 2018-01-26Updated: 2020-03-10

Related Papers

Efficacy and Safety of Octanorm (cutaquig <sup>®</sup> ) in Adults with Primary Immunodeficiencies with Predominant Antibody Deficiency: A Prospective, Open-Label Study

Immunotherapy2020-03-268 citations